In the TCGA pan‐cancer datasets, THYM patients with the T3 subtype exhibited the highest expression of CCL20, as well as the highest CCL20‐CCR6 ligand‐receptor pair score (Figure S12c, Supporting Information). This evidence concerns the gene CCL20 and cancer.